Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90).
Retinitis pigmentosa (RP) is the most prevalent cause of registered visual handicap among working aged populations of developed countries. Up to 40% of autosomal dominant cases of disease are caused by mutations within the rhodopsin, RDS-peripherin and inosine 5'-monophosphate dehydrogenase type 1 (IMPDH1) genes, at least 30 mutations within which give rise to proteins that cause disease pathology by misfolding and aggregation. Given the genetic complexity of this disease, therapies that simultaneously target multiple mutations are of substantial logistic and economic significance. We show here, in a murine model of autosomal dominant RP (RP10) involving expression of an Arg224Pro mutation within the IMPDH1 gene, that treatment with the low-molecular-weight drug, 17-allylamino-17-demethoxygeldanamycin (17-AAG), an ansamycin antibiotic that binds to heat shock protein Hsp90, activating a heat shock response in mammalian cells, protects photoreceptors against degeneration induced by aggregating mutant IMPDH1 protein, systemic delivery of this low-molecular-weight drug to the retina being facilitated by RNA interference-mediated modulation of the inner-blood retina barrier. 17-AAG has an orphan drug status and is in current clinical use for the treatment of non-ocular diseases. These data show that a single low-molecular-weight drug has the potential to suppress a wide range of mutant proteins causing RP.
Tam
Lawrence C S
LC
The Ocular Genetics Unit, Department of Genetics, Trinity College Dublin, Dublin 2, Ireland.
Kiang
Anna-Sophia
AS
Campbell
Matthew
M
Keaney
James
J
Farrar
G Jane
GJ
Humphries
Marian M
MM
Kenna
Paul F
PF
Humphries
Pete
P
D000818:Animals; D016227:Benzoquinones / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D005799:Genes, Dominant; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D007168:IMP Dehydrogenase / Q000235:genetics / Q000378:metabolism; D047029:Lactams, Macrocyclic / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D009154:Mutation; D034622:RNA Interference; D012160:Retina / Q000187:drug effects; D012174:Retinitis Pigmentosa / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D012243:Rhodopsin / Q000235:genetics / Q000378:metabolism
D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; C112765:tanespimycin; D012243:Rhodopsin; D007168:IMP Dehydrogenase
J Biol Chem. 1994 Dec 9;269(49):30761-4
7983002
Cancer Chemother Pharmacol. 2001 Apr;47(4):291-302
11345645
Cell Mol Life Sci. 2005 Mar;62(6):670-84
15770419
J Gene Med. 2008 Aug;10(8):930-47
18509865
Nat Genet. 1997 Feb;15(2):216-9
9020854
Cancer Chemother Pharmacol. 2005 Aug;56(2):115-25
15791458
J Biol Chem. 2008 Sep 19;283(38):26188-97
18632670
N Engl J Med. 2008 May 22;358(21):2231-9
18441371
Nature. 1995 Jul 6;376(6535):37-43
7596430
Annu Rev Genet. 1993;27:437-96
8122909
Hum Mol Genet. 2004 Jul 1;13(13):1389-405
15115766
Am J Hum Genet. 2007 Jul;81(1):127-35
17564969
Nat Med. 2006 Jan;12(1):128-32
16327803
Exp Biol Med (Maywood). 2003 Feb;228(2):111-33
12563018
Nat Med. 2005 Oct;11(10):1088-95
16155577
Hum Mol Genet. 2009 Mar 1;18(5):898-910
19066230
Lancet. 2009 Nov 7;374(9701):1597-605
19854499
Nat Genet. 1999 Dec;23(4):425-8
10581028
Neurodegener Dis. 2007;4(2-3):254-60
17596719
Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5961-6
20231467
Hum Gene Ther. 2009 Sep;20(9):999-1004
19583479
BMC Neurosci. 2008 Dec 03;9 Suppl 2:S5
19090993
Leukemia. 2010 Apr;24(4):699-705
20111068
Curr Opin Drug Discov Devel. 2009 Sep;12(5):666-81
19736625
Cancer Lett. 2010 Apr 1;290(1):24-35
19850405
Prog Retin Eye Res. 2008 Jul;27(4):434-49
18490186
J Clin Invest. 2007 Mar;117(3):648-58
17304350
Nature. 1991 Dec 12;354(6353):478-80
1749427
J Biol Chem. 2002 Sep 13;277(37):34150-60
12091393
Hum Mol Genet. 2001 Jun 1;10(12):1307-15
11406612
Hum Mol Genet. 2008 Jul 15;17(14):2084-100
18385099
J Cell Sci. 2002 Jul 15;115(Pt 14):2907-18
12082151
BMC Bioinformatics. 2007 Feb 27;8:65
17324296
Clin Cancer Res. 2005 May 1;11(9):3385-91
15867239
Neuron. 1992 Nov;9(5):815-30
1418997
J Clin Oncol. 2005 Feb 20;23(6):1078-87
15718306
Hum Mol Genet. 2000 Nov 22;9(19):2811-20
11092757
Cell. 1998 Aug 21;94(4):471-80
9727490
Clin Lymphoma Myeloma. 2006 May;6(6):500-1
16796784
Mol Biol Cell. 2008 Mar;19(3):899-911
18094050
Nature. 2002 Aug 15;418(6899):729-30
12181546
Bioinformatics. 2009 Oct 1;25(19):2537-43
19654118
Hum Mol Genet. 2002 Mar 1;11(5):547-57
11875049
J Biol Chem. 2008 Dec 26;283(52):36354-60
18974094
Curr Cancer Drug Targets. 2003 Oct;3(5):377-83
14529389
Lancet. 2006 Nov 18;368(9549):1795-809
17113430
Clin Cancer Res. 2007 Apr 1;13(7):2261-70
17404111
Hum Mol Genet. 2008 Oct 1;17(19):3043-54
18635576
Adv Cancer Res. 2006;95:323-48
16860662
Neuropathol Appl Neurobiol. 1993 Feb;19(1):10-21
8386339
Hum Mol Genet. 2004 Mar 15;13(6):641-50
14981049
Nature. 1990 Jan 25;343(6256):364-6
2137202
Biochemistry. 2010 Feb 9;49(5):905-11
20055437
J Neurochem. 2002 Apr;81(2):355-64
12064483
Nat Rev Mol Cell Biol. 2004 Oct;5(10):781-91
15459659
Genet Med. 2005 Jan;7(1):3-12
15654222
Am J Med Genet A. 2003 Jul 30;120A(3):320-5
12838549
Brain Res Bull. 2010 Jan 15;81(1):12-24
19808079
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17817-22
19822744
Trends Mol Med. 2005 Apr;11(4):177-85
15823756
Hum Mol Genet. 2002 Mar 1;11(5):559-68
11875050
Nat Med. 2004 Jul;10 Suppl:S10-7
15272267
Mol Ther. 2005 Sep;12(3):555-61
15967729
Nat Med. 2002 Nov;8(11):1185-6
12411925
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2878-87
18408180